Oculis Holding AG (OCS) vs Phathom Pharmaceuticals, Inc. (PHAT)

Oculis Holding AG and Phathom Pharmaceuticals, Inc. are both Biotechnology companies. Oculis Holding AG and Phathom Pharmaceuticals, Inc. are of similar size ($421.6M and $413.0M). Phathom Pharmaceuticals, Inc. grew revenue faster over the last twelve months: 86.8% against 25.0%. Phathom Pharmaceuticals, Inc. has the higher net margin (−30.2% vs −8,709.4%) and the higher return on invested capital (0.00% vs −12,858.7%). Across the 16 metrics below, Phathom Pharmaceuticals, Inc. leads on 14 and Oculis Holding AG on 2.

Valuation

Metric OCS PHAT Biotechnology median
P/E n/m n/m 10.60
P/S 393.17 1.62 9.40
P/B 1.80 n/m 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales 175.67 1.58 9.02
Earnings yield (23.24%) (19.76%) (32.88%)
Free cash flow yield (18.69%) (4.74%) (23.13%)

Profitability

Metric OCS PHAT Biotechnology median
Gross margin 100.00% 80.68% 68.51%
Operating margin (9,551.41%) (9.26%) 0.00%
Net margin (8,709.42%) (30.19%) 0.00%
Free cash flow margin (7,237.57%) (7.65%) 0.00%
Return on equity (48.81%) 21.55% (51.96%)
Return on assets (41.38%) (28.36%) (46.06%)
Return on invested capital (12,858.67%) 0.00% 0.00%

Growth

Metric OCS PHAT Biotechnology median
Revenue growth (TTM) 25.01% 86.75% 6.76%
EPS growth (last fiscal year) 5.39% 42.72% 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric OCS PHAT Biotechnology median
Debt to equity 0.01 (0.48) 0.00
Current ratio 10.41 1.76 4.97
Net debt to EBITDA 2.60 (0.51) 1.01

Dividend

Metric OCS PHAT Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric OCS PHAT Biotechnology median
Market cap 421.63m 412.96m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack